When did Lexicon Pharmaceuticals report Q4 2024 earnings?

Lexicon Pharmaceuticals (LXRX) reported Q4 2024 earnings on March 6, 2025 after market close.

What were Lexicon Pharmaceuticals's Q4 2024 revenue and EPS?

Lexicon Pharmaceuticals reported revenue of $26.6M and eps of $-0.09 for Q4 2024.

Did Lexicon Pharmaceuticals beat estimates in Q4 2024?

Revenue beat the consensus estimate of $2.8M by $23.7M. EPS beat the consensus estimate of $-0.11 by $0.02.

Where can I find Lexicon Pharmaceuticals's Q4 2024 SEC filings?

You can read the 10-K periodic report (0001062822-25-000013) directly on SEC EDGAR. The filing index links above go to sec.gov.

Lexicon Pharmaceuticals LXRX Q4 2024 Annual earnings

Reported March 6, 2025 · After market close

Revenue$26.6MBeat by $23.7M

EPS-$0.09Beat by $0.02

Revenue estimate$2.8M

EPS estimate-$0.11

Next report

Aug 5, 2026 (In 6 days)

Revenue estimate$4.0M

EPS estimate-$0.06

Financials

Q4 2024

Income statement

See full

Revenue$26.6M+3,683%

Gross profit$26.2M+4,047%

Operating income-$32.7M+30.0%

Net income-$33.8M+32.1%

EPS (diluted)-$0.09+55.0%

Balance sheet

See full

Cash & equivalents$66.7M+197%

Total debt$106.1M0.0%

Total equity$146.0M+56.8%

Total assets$298.4M+30.1%

Cash flow

See full

Operating cash flow-$21.5M+57.5%

CapEx$474.0K—

Free cash flow-$22.0M+56.5%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$266.96M-28.8%

Enterprise value$306.38M-33.2%

P/S8.6×-302×

Profitability

See full

Gross margin98%+5.1pp

Operating margin-634.2%-310pp

Net margin-644.8%-315pp

FCF margin-578.5%-283pp

Returns & leverage

See full

Return on equity-167.7%-0.8pp

Debt / equity0.7×-0.4×

Current ratio5.4×-0.2×

Segments

By segment

See full

Reportable Segment$26.6M+8,722%

By product

See full

License$25.0M—

Versus estimates

Revenue

Q1 2026$21.1MBeat by $11.3M Q4 2025$5.5MBeat by $2.4M Q3 2025$14.2MBeat by $11.0M Q2 2025$28.9MBeat by $23.1M Q1 2025$1.3MMiss by $44.7K

Q4 2024$26.6MBeat by $23.7M

Diluted EPS

Q1 2026-$0.00Beat by $0.04 Q4 2025-$0.04Beat by $0.03 Q3 2025-$0.04Beat by $0.03 Q2 2025$0.01Beat by $0.09 Q1 2025-$0.07Beat by $0.03

Q4 2024-$0.09Beat by $0.02

Ask the moment Lexicon Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Lexicon Pharmaceuticals report Q4 2024 earnings?: Lexicon Pharmaceuticals (LXRX) reported Q4 2024 earnings on March 6, 2025 after market close.
What were Lexicon Pharmaceuticals's Q4 2024 revenue and EPS?: Lexicon Pharmaceuticals reported revenue of $26.6M and eps of $-0.09 for Q4 2024.
Did Lexicon Pharmaceuticals beat estimates in Q4 2024?: Revenue beat the consensus estimate of $2.8M by $23.7M. EPS beat the consensus estimate of $-0.11 by $0.02.
Where can I find Lexicon Pharmaceuticals's Q4 2024 SEC filings?: You can read the 10-K periodic report (0001062822-25-000013) directly on SEC EDGAR. The filing index links above go to sec.gov.